Oruka Therapeutics, Inc. (ORKA)
| Market Cap | 3.63B +812.2% |
| Revenue (ttm) | n/a |
| Net Income | -94.19M |
| EPS | -1.92 |
| Shares Out | 60.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,301,594 |
| Open | 63.04 |
| Previous Close | 62.28 |
| Day's Range | 59.30 - 63.92 |
| 52-Week Range | 10.77 - 91.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 142.17 (+136.4%) |
| Earnings Date | May 13, 2026 |
About ORKA
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price target is $142.17, which is an increase of 136.40% from the latest price.
News
Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing best-in-class IL-23 and IL-17A/F therapies for psoriatic disease, with phase II data showing high efficacy and flexible dosing options. Key upcoming milestones include additional EVERLAST-A data, phase III readiness, and expansion into new indications, all supported by strong financials.
Oruka Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and addressed three proposals: director elections, auditor ratification, and executive compensation. All proposals passed, with final vote totals to be filed with the SEC.
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard...
Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)
“This was an important period for our company as we saw interim data for ORKA-001 that hit the upper end of our expectations on all aspects,” said Lawrence Klein, Chief…
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Oruka Therapeutics Quarterly report: Q1 2026
Oruka Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Oruka Therapeutics Earnings release: Q1 2026
Oruka Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. ...
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na...
Oruka Therapeutics price target raised to $120 from $109 at Leerink
Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $109 and keeps an Outperform rating on the shares.
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Oruka Therapeutics (ORKA) to $120 from $75 and keeps a Buy rating on the shares. The EVERLAST-A “delivers in spades,” positioning ORKA-001…
Oruka Therapeutics $700M Secondary priced at $72.50
Leerink, TD Cowen, Goldman Sachs, Stifel and Guggenheim acted as joint book running managers for the offering.
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics ...
Oruka Therapeutics price target raised to $100 from $75 at UBS
UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $100 from $75 and keeps a Buy rating on the shares. Oruka reported stronger than expected data for PASI-100,…
Oruka Therapeutics announces $500M common stock, warrants offering
Oruka Therapeutics (ORKA) announced that it has commenced an underwritten public offering of $500M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded…
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics ...
Oruka Therapeutics price target raised to $131 from $71 at Clear Street
Clear Street raised the firm’s price target on Oruka Therapeutics (ORKA) to $131 from $71 and keeps a Buy rating on the shares. The firm says the company’s interim EVERLAST-A…
Oruka Therapeutics rises 19.0%
Oruka Therapeutics (ORKA) is up 19.0%, or $13.12 to $82.15.
Oruka Therapeutics price target raised to $160 from $78 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Oruka Therapeutics (ORKA) to $160 from $78 and keeps an Overweight rating on the shares. The firm upped the price…
Oruka Therapeutics price target raised to $165 from $85 at Wedbush
Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $165 from $85 and keeps an Outperform rating on the shares. The firm upped the price target after Oruka…
Oruka Therapeutics price target raised to $200 from $125 at Guggenheim
Guggenheim raised the firm’s price target on Oruka Therapeutics (ORKA) to $200 from $125 and keeps a Buy rating on the shares. The firm believes ORKA-001 has “multibillion blockbuster potential”…
Oruka Therapeutics rises 23.5%
Oruka Therapeutics (ORKA) is up 23.5%, or $16.23 to $85.26.
Oruka Therapeutics price target raised to $151 from $78 at BTIG
BTIG raised the firm’s price target on Oruka Therapeutics (ORKA) to $151 from $78 and keeps a Buy rating on the shares. The firm notes that 16 weeks results from…
This Is Why Oruka Therapeutics Stock (ORKA) Soared Today
Oruka Therapeutics stock soared after the company announced strong clinical trial results.
Oruka Therapeutics announces interim results from EVERLAST-A trial
Oruka Therapeutics (ORKA) announced interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis. Ove...